Target Name: TECRL
NCBI ID: G253017
Review Report on TECRL Target / Biomarker Content of Review Report on TECRL Target / Biomarker
TECRL
Other Name(s): Steroid 5 alpha-reductase 2-like 2 | Steroid 5-alpha-reductase 2-like 2 protein | GPSN2L | steroid 5 alpha-reductase 2-like 2 | TERL | steroid 5-alpha-reductase 2-like 2 protein | TECRL_HUMAN | Trans-2,3-enoyl-CoA reductase-like | Trans-2,3-enoyl-CoA reductase like, transcript variant 1 | trans-2,3-enoyl-CoA reductase like | Glycoprotein, synaptic 2-like | Trans-2,3-enoyl-CoA reductase-like (isoform 1) | SRD5A2L2 | CPVT3 | glycoprotein, synaptic 2-like | TECRL variant 1

TECRL: A Potential Drug Target for Various Diseases

TECRL (Steroid 5 alpha-reductase 2-like 2) is a protein that is expressed in various tissues throughout the body. It is a key enzyme in the steroid biosynthesis pathway, which is responsible for converting and metabolizing steroids. TECRL plays a crucial role in this process by catalyzing the conversion of and to 21-hydroxylated steroids.

Recent studies have identified TECRL as a potential drug target for the treatment of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The ability of TECRL to regulate steroid biosynthesis and its involvement in the production of androgens, which are involved in the development and progression of these diseases make it an attractive target for drug development.

One of the key advantages of TECRL as a drug target is its specificity. Unlike many other proteins that have been identified as drug targets, TECRL is highly specific for its target, which allows for the development of highly effective therapies. The specificity of TECRL makes it an attractive target for the treatment of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, which are characterized by the progressive loss of brain cells.

Another advantage of TECRL is its involvement in the production of androgens. Androgens are involved in the development and maintenance of various physiological processes in the body, including sexual function, bone growth, and wound healing. The production of androgens is a critical step in the steroid biosynthesis pathway, and TECRL's role in this process makes it an attractive target for the treatment of androgen-related disorders, such as androgen insensitivity syndrome and hirsutism.

In addition to its involvement in the production of androgens, TECRL has also been shown to play a role in the regulation of cell growth and differentiation. Studies have shown that TECRL can inhibit the growth of cancer cells and promote the apoptosis, or programmed cell death, of these cells. This makes it an attractive target for the treatment of cancer, including breast, ovarian, and prostate cancer.

Another potential mechanism by which TECRL may be involved in the development and progression of neurodegenerative diseases is its role in the production of neurotransmitters, such as dopamine and testosterone. The production of these neurotransmitters is closely regulated by the levels of androgens, and TECRL's role in this process makes it an attractive target for the treatment of neurodegenerative diseases.

In conclusion, TECRL is a protein that is expressed in various tissues throughout the body and plays a crucial role in the steroid biosynthesis pathway. Its specificity and involvement in the production of androgens, as well as its potential role in the regulation of cell growth and differentiation, make it an attractive target for the development of new therapies for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Further research is needed to fully understand the role of TECRL in these diseases and to develop effective therapies.

Protein Name: Trans-2,3-enoyl-CoA Reductase Like

The "TECRL Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TECRL comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

TECTA | TECTB | TEDC1 | TEDC2 | TEDC2-AS1 | TEDDM1 | TEF | TEFM | TEK | TEKT1 | TEKT2 | TEKT3 | TEKT4 | TEKT4P1 | TEKT4P2 | TEKT5 | TEKTIP1 | TELO2 | Telomerase holoenzyme complex | TEN1 | TEN1-CDK3 | Teneurin | TENM1 | TENM2 | TENM2-AS1 | TENM3 | TENM3-AS1 | TENM4 | TENT2 | TENT4A | TENT4B | TENT5A | TENT5B | TENT5C | TENT5C-DT | TENT5D | TEP1 | TEPP | TEPSIN | TERB1 | TERB2 | TERC | TERF1 | TERF1P3 | TERF2 | TERF2IP | TERLR1 | TERT | TES | TESC | TESK1 | TESK2 | TESMIN | TESPA1 | TET1 | TET2 | TET2-AS1 | TET3 | Tetraspanin | TEX10 | TEX101 | TEX11 | TEX12 | TEX13A | TEX13B | TEX13C | TEX14 | TEX15 | TEX19 | TEX2 | TEX21P | TEX22 | TEX26 | TEX261 | TEX264 | TEX28 | TEX29 | TEX30 | TEX33 | TEX35 | TEX36 | TEX36-AS1 | TEX37 | TEX38 | TEX41 | TEX43 | TEX44 | TEX45 | TEX46 | TEX47 | TEX48 | TEX49 | TEX50 | TEX52 | TEX53 | TEX55 | TEX56P | TEX9 | TF | TFAM